Advanced Cholangiocarcinoma Clinical Trial
Official title:
A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib Versus Gemcitabine With Cisplatin in Subjects With Advanced/Metastatic or Inoperable Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations: The PROOF Trial
Verified date | April 2024 |
Source | QED Therapeutics, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Infigratinib is an oral drug which selectively binds to fibroblast growth factor receptor (FGFR) 2 and is being developed to treat participants with FGFR2 mutated cholangiocarcinoma. The purpose of the study is to evaluate the efficacy and safety of the investigational agent oral infigratinib vs standard of care chemotherapy (gemcitabine plus cisplatin) in first-line treatment of participants with unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion/rearrangement. Subjects will be randomized 2:1 to receive infigratinib or gemcitabine plus cisplatin.
Status | Terminated |
Enrollment | 48 |
Est. completion date | March 2, 2023 |
Est. primary completion date | March 2, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Histologically or cytologically confirmed unresectable locally advanced or metastatic cholangiocarcinoma. Participants with gallbladder cancer or ampulla of Vater carcinoma are not eligible - Have written documentation of local laboratory or central laboratory determination of a known or likely activating FGFR2 fusion/rearrangement from a sample collected before randomization - Have an archival tumor tissue sample available with sufficient tumor content for FGFR2 fusion/rearrangement molecular testing by the central laboratory. However, if an archival tumor tissue sample is not available, or does not meet requirements for central testing a newly obtained (before randomization) tumor biopsy may be submitted instead. If a prestudy written documentation of FGFR2 fusion/rearrangement in tumor tissue is available from the central laboratory, an additional tumor sample does not need to be submitted. - Have an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 - Are able to swallow and retain oral medication - Are willingness to avoid pregnancy or father children Exclusion Criteria: - Received treatment with any systemic anti-cancer therapy for unresectable locally advanced or metastatic cholangiocarcinoma, with following exceptions 1. Prior neoadjuvant or adjuvant therapy is permitted if completed > 6 months after the last dose of neoadjuvant or adjuvant therapy. 2. One cycle of gemcitabine-based chemotherapy for locally advanced or metastatic cholangiocarcinoma is permitted before randomization - History of a liver transplant - Received previously or currently is receiving treatment with a mitogen activated protein kinase kinase (MEK) or selective FGFR inhibitor - Have impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral infigratinib (such as, ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection). - Current evidence of endocrine alterations of calcium/phosphate homeostasis, e.g., parathyroid disorders, history of parathyroidectomy, tumor lysis, tumoral calcinosis etc. - History and/or current evidence of extensive tissue calcification including, but not limited to, the soft tissue, kidneys, intestine, myocardium, vascular system and lung with the exception of calcified lymph nodes, minor pulmonary parenchymal calcifications, and asymptomatic coronary calcification - Current evidence of corneal or retinal disorder/keratopathy - Receiving and continued treatment or are planning to receive agents or consuming foods that are known moderate or strong inducers or inhibitors of CYP3A4 and medications which increase serum phosphorus and/or calcium concentration - Clinically significant or uncontrolled cardiac disease - Recent (= 3 months prior to first dose of study drug) transient ischemic attack or stroke - Severe hearing loss - Severe neuropathy - History of another primary malignancy within 3 years except adequately treated in-situ carcinoma of the cervix or non-melanoma skin cancer or other curatively treated malignancy that is not expected to require treatment - Pregnant or breastfeeding - Have known microsatellite instability-high (MSI-H) disease and the decision is made by the treating investigator that an alternative, non-study therapy is warranted according to standard of care. - Have any known hypersensitivity to gemcitabine, cisplatin, calcium-lowering agents, infigratinib, or their excipients - Have any contraindication to cisplatin or gemcitabine treatment according to local labeling or standard institutional practice. - Have taken any Chinese herbal medicine or Chinese patent medicine treatments with anticancer activity within 14 days of the first dose of study drug. - Have received a live vaccine within 30 days before the first dose of study drug or are planning to receive a live vaccine during participation in this study |
Country | Name | City | State |
---|---|---|---|
Australia | Royal Adelaide Hospital | Adelaide | South Australia |
Australia | Monash Medical Centre | Bentleigh East | Victoria |
Australia | Chris O'Brien Lifehouse Hospital | Camperdown | New South Wales |
Australia | Blacktown Hospital | Darlinghurst | New South Wales |
Australia | Peninsula & South Eastern Haematology and Oncology Group | Frankston | Victoria |
Australia | St John of God Hospital Subiaco | Subiaco | Western Australia |
Belgium | Cliniques Universitaires Saint-Luc | Bruxelles | Brussels |
Belgium | Grand Hopital de Charleroi | Charleroi | |
Belgium | Universitair Ziekenhuis Antwerpen | Edegem | |
Canada | Cross Cancer Institute | Edmonton | Alberta |
Canada | Jewish General Hospital | Montréal | Quebec |
Canada | Ottawa Hospital | Ottawa | Ontario |
Canada | St. Josephs Health Centre | Toronto | Ontario |
China | Beijing Cancer Hospital | Beijing | |
China | Peking University People's Hospital | Beijing | |
China | Peking University Third Hospital | Beijing | |
China | Hunan Cancer Hospital | Changsha | |
China | Guangzhou First People's Hospital | Guangzhou | |
China | Hubei Cancer Hospital | Hubei | |
China | Liaoning Cancer Hospital & Institute | Shenyang | |
China | The First Affiliated Hospital, Sun Yat-sen University | Zhongshan | |
France | Hopital Henri Mondor | Créteil | Val-de-Marne |
France | Centre Georges-Francois Leclerc | Dijon | |
France | CHRU Dijon | Dijon | |
France | Hopital Claude Huriez Rue Michel Polonovski (CHRU) Lille | Lille | |
France | Groupement Hospitalier Edouard Herriot | Lyon | |
France | Hopital Nord Franche-Comte | Montbéliard | |
France | Groupe Hospitalier Archet I Et II | Nice | |
France | Hopital Cochin | Paris | |
France | Hôpital Saint Antoine | Paris | |
France | L'Institut Mutualiste Montsouris | Paris | |
Germany | Klinikum Dortmund gGmbH | Dortmund | |
Germany | University Clinic Heidelberg | Heidelberg | |
Germany | Klinikum rechts der Isar der Technischen Universität München | München | Bayern |
Germany | Universitätsklinikum Tübingen | Tübingen | Baden-Wurttemberg |
Italy | Azienda Socio Sanitaria Territoriale di Cremona (ASST) | Cremona | |
Italy | Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori IRST | Meldola | |
Italy | ASST Grande Ospedale Metropolitano Niguarda | Milano | |
Italy | Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico | Milano | |
Italy | Istituto Oncologico Veneto - I.R.C.C.S. | Padova | |
Italy | Policlinico Universitario Campus Biomedico Di Roma | Roma | |
Korea, Republic of | Pusan National University Hospital | Pusan | |
Korea, Republic of | Seoul National University Bundang Hospital | Seongnam-si | |
Korea, Republic of | Samsung Medical Center | Seoul | |
Korea, Republic of | Seoul National University Hospital | Seoul | |
Korea, Republic of | Severance Hospital Yonsei University Health System | Seoul | |
Korea, Republic of | SMG - SNU Boramae Medical Center | Seoul | |
Korea, Republic of | The Catholic University of Korea, Seoul St. Mary's Hospital | Seoul | |
Korea, Republic of | Ajou University Hospital | Suwon-si | |
Portugal | Hospital Garcia de Orta | Almada | |
Portugal | Centro Hospitalar E Universitário de Coimbra EPE | Coimbra | |
Portugal | Instituto Português de Oncologia Francisco Gentil Centro Regional de Oncologia de Coimbra EPE | Coimbra | |
Portugal | Centro Hospitalar Lisboa Norte, E.P.E. - Hospital de Santa Maria | Lisboa | |
Portugal | Hospital CUF Descobertas | Lisboa | |
Portugal | Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E. | Lisbon | |
Portugal | Hospital Beatriz Angelo | Loures | Lisboa |
Portugal | Centro Hospitalar de São João, E.P.E. | Porto | |
Portugal | Centro Hospitalar do Porto - Hospital de Santo António | Porto | |
Portugal | Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe - PPDS | Porto | |
Puerto Rico | Hospital Oncologico, Puerto Rico Medical Center | Rio Piedras | |
Spain | Hospital Universitario Germans Trias i Pujol | Badalona | Cataluna |
Spain | Hospital Universitario Vall d'Hebrón - PPDS | Barcelona | |
Spain | Instituto Catalan de Oncologio ICO I'Hospitalet | Barcelona | Cataluna |
Spain | Hospital General Universitario Gregorio Maranon | Madrid | |
Spain | Hospital Universitario 12 de Octubre | Madrid | |
Spain | Hospital Universitario HM Sanchinarro - CIOCC | Madrid | |
Spain | Hospital Universitario La Paz | Madrid | |
Spain | Hospital Universitario Ramon y Cajal | Madrid | |
Spain | Complejo Asistencial Universitario de Salamanca - Hospital Clinico | Salamanca | Castilla Y Leon |
Spain | Hospital Universitario Virgen Macarena | Sevilla | Andalucia |
Spain | Hospital Universitari i Politecnic La Fe de Valencia | Valencia | |
Spain | Hospital Universitario Miguel Servet | Zaragoza | Aragon |
Taiwan | National Taiwan University Hospital - YunLin Branch | Huwei | |
Taiwan | Chang Gung Memorial Hospital - Kaohsiung | Kaohsiung | |
Taiwan | China Medical University Hospital | Taichung City | |
Taiwan | Chi Mei Hospital, Liouying | Tainan | |
Taiwan | National Cheng Kung University Hospital | Tainan City | Tainan |
Taiwan | National Taiwan University Hospital | Taipei | |
Taiwan | Taipei Veterans General Hospital | Taipei | |
Taiwan | Chang Gung Memorial Hospital, Linkou | Taoyuan City | |
Thailand | Chulalongkorn University | Bangkok | |
Thailand | Ramathibodi Hospital Mahidol University | Bangkok | |
Thailand | Maharaj Nakorn Chiang Mai Chiang Mai University | Chiang Mai | |
Thailand | Songklanagarind Hospital, Prince of Songkla University | Hat Yai | Songkla |
Thailand | Srinagarind Hospital | Khon Kaen | |
Thailand | Naresuan University | Phitsanulok | |
United Kingdom | The Clatterbridge Cancer Centre NHS Foundation Trust | Bebington | Wirral |
United Kingdom | Guys Hospital | London | |
United Kingdom | The Christie NHS Foundation Trust - PPDS | Manchester | |
United Kingdom | Nottingham City Hospital | Nottingham | Nottinghamshire |
United Kingdom | Royal Marsden Hospital | Sutton | Surrey |
United States | Massachusetts General Hospital | Boston | Massachusetts |
United States | Charleston Oncology | Charleston | South Carolina |
United States | Levine Cancer Institute - Charlotte | Charlotte | North Carolina |
United States | Northwestern Memorial Hospital | Chicago | Illinois |
United States | University of Cincinnati Medical Center | Cincinnati | Ohio |
United States | Ohio State University Comprehensive Cancer Center | Columbus | Ohio |
United States | Parkland Health and Hospital System | Dallas | Texas |
United States | University of Texas Southwestern Medical Center | Dallas | Texas |
United States | Barbara Ann Karmanos Cancer Institute - Lawrence and Idell Weisberg Cancer Treatment Center | Detroit | Michigan |
United States | Frederick Regional Healthcare Systems/James M. Stockman Cancer Institute | Frederick | Maryland |
United States | St. Joseph Heritage Healthcare | Fullerton | California |
United States | Banner MD Anderson Cancer Center | Gilbert | Arizona |
United States | Cancer and Hematology Centers of Western Michigan | Grand Rapids | Michigan |
United States | Baylor College of Medicine | Houston | Texas |
United States | University of Texas MD Anderson Cancer Center | Houston | Texas |
United States | University of Arkansas for Medical Sciences | Little Rock | Arkansas |
United States | University of California Los Angeles | Los Angeles | California |
United States | USC Norris Cancer Center | Los Angeles | California |
United States | University Medical Center - New Orleans | New Orleans | Louisiana |
United States | Memorial Sloan Kettering Cancer Center | New York | New York |
United States | NYU Langone Medical Center | New York | New York |
United States | Florida Hospital Medical Group | Orlando | Florida |
United States | UF Health Cancer Center at Orlando Health | Orlando | Florida |
United States | William Beaumont Hospital | Royal Oak | Michigan |
United States | University of Arizona | Tucson | Arizona |
Lead Sponsor | Collaborator |
---|---|
QED Therapeutics, Inc. | Helsinn Healthcare SA |
United States, Australia, Belgium, Canada, China, France, Germany, Italy, Korea, Republic of, Portugal, Puerto Rico, Spain, Taiwan, Thailand, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-free Survival (Central Imaging Assessment) | Defined as the time from randomization until date of disease progression by blinded independent central imaging assessment (Response Evaluation Criteria in Solid Tumors [RECIST] v. 1.1) or death, whichever occurs first. | From the time of randomization to end of treatment due to confirmed disease progression or death. Note: PFS is an event driven endpoint. Subjects without confirmed disease progression at the end of study were censored at their last valid tumor assessment. | |
Secondary | Overall Survival (OS) in Participants Treated With Infigratinib Versus Gemcitabine With Cisplatin | OS by investigator assessment, defined as time from date of randomization until death due to any cause | From the time of randomization to time of death. Note: OS is an event driven endpoint. Subjects who had not died (no record of death) or were lost to follow-up were censored at the date of last known to be alive. | |
Secondary | Investigator Assessed Progression Free Survival in Participants Treated With Infigratinib Compared to Gemcitabine and Cisplatin | Defined as the time from randomization until date of disease progression by site investigator (RECIST v1.1) or death, whichever occurs first. | From the time of randomization to end of treatment due to confirmed disease progression or death. Note: PFS is an event driven endpoint. Subjects without confirmed disease progression at the end of study were censored at their last valid tumor assessment. | |
Secondary | Overall Response Rate (ORR) Determined by Blinded Independent Central (BICR) and Investigator Assessment | ORR is defined as the proportion of subjects with a best overall response (BOR) of either confirmed partial response (PR) or confirmed complete response (CR) as assessed by BICR and the investigator according to RECIST v1.1 among patients with measurable disease at baseline | From the time of randomization to end of study treatment (an average of approx.6.5 months [max: 23 months] for the infigratinib arm and approx. 4 months [max: 11-13 months] for the gemcitabine + cisplatin arm up to the time of termination of the study). | |
Secondary | Best Overall Response (BOR) Determined by Blinded Independent Central Assessment and the Investigator. | BOR was defined as the best response a subject ever achieved after study treatment prior to crossover and any subsequent anticancer therapy, complete response (CR) and partial response (PR) were claimed only if the criteria for each were met at a subsequent time point at least 4 weeks apart. In the case of stable disease (SD), measurements must have met the SD criteria at least once post-baseline no less than 6 weeks from the randomization date. | From the time of randomization to end of study treatment (an average of approx.6.5 months [max: 23 months] for the infigratinib arm and approx. 4 months [max: 11-13 months] for the gemcitabine + cisplatin arm up to the time of termination of the study). | |
Secondary | Duration of Response (DOR) Determined by Blinded Independent Central Assessment and the Investigator. | DOR is defined as the time from initiation of confirmed partial response (PR) or confirmed complete response (CR) to the time of confirmed progressive disease (PD) or death. If subjects do not reach PD or death before crossover, the DOR is censored at the last valid tumor assessment before crossover. | From the time of randomization to end of study treatment (an average of approx.6.5 months [max: 23 months] for the infigratinib arm and approx. 4 months [max: 11-13 months] for the gemcitabine + cisplatin arm up to the time of termination of the study). | |
Secondary | Disease Control Rate (DCR=PR+CR+SD) Determined by Blinded Independent Central Assessment and the Investigator. | DCR is defined as the proportion of subjects with a best overall response (BOR) of either confirmed partial response (PR), confirmed complete response (CR) or stable disease (SD) or non-CR/non-PD before crossover. | From the time of randomization to end of study treatment (an average of approx.6.5 months [max: 23 months] for the infigratinib arm and approx. 4 months [max: 11-13 months] for the gemcitabine + cisplatin arm up to the time of termination of the study). | |
Secondary | Number of Participants With Adverse Events (AEs) | Safety analyses were performed for subjects in the safety analysis population for each group. Unless otherwise specified, summaries were provided only for the on-treatment safety assessments, which are the assessments occurring or taken during the on-treatment period | From baseline to last dose date of study treatment + 30 days (an average of 7.5 months for the infigratinib arm and 5 months for the gemcitabine + cisplatin arm). | |
Secondary | Number of Participants With Serious Adverse Events (SAEs) | Safety analyses were performed for subjects in the safety analysis population for each group. Unless otherwise specified, summaries were provided only for the on-treatment safety assessments, which are the assessments occurring or taken during the on-treatment period | From baseline to last dose date of study treatment + 30 days (an average of 7.5 months for the infigratinib arm and 5 months for the gemcitabine + cisplatin arm). |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05823311 -
Lenvatinib, Tislelizumab Combined With Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma
|
Phase 3 | |
Not yet recruiting |
NCT06439485 -
Phase II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion
|
Phase 2 | |
Recruiting |
NCT06420349 -
NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma
|
Phase 1 | |
Recruiting |
NCT05727176 -
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
|
Phase 2 | |
Recruiting |
NCT05791448 -
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
|
Phase 1 | |
Active, not recruiting |
NCT04093362 -
Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
|
Phase 3 | |
Recruiting |
NCT03996408 -
Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Cholangiocarcinoma
|
Phase 1/Phase 2 | |
Terminated |
NCT02982720 -
Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron
|
Phase 2 | |
Terminated |
NCT02150967 -
A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma
|
Phase 2 | |
Recruiting |
NCT03982680 -
Toripalimab Combined With Gemcitabine/5--fluoropyrimidine for Advanced Cholangiocarcinoma
|
Phase 2 | |
Recruiting |
NCT05532059 -
Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients With Advanced Cholangiocarcinoma
|
Phase 2 | |
Terminated |
NCT04088188 -
Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma
|
Phase 1 | |
Completed |
NCT02989857 -
Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)
|
Phase 3 | |
Recruiting |
NCT05805956 -
IMM2902 in Patients With Advanced Solid Tumors Expressing HER2
|
Phase 1/Phase 2 | |
Approved for marketing |
NCT04507503 -
Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
|